Search PubMed⌕ Search

Biomedical subjects

H Okada

Publications and source records attributed to H Okada.

At least 559 records · Page 31Linked to original sources
PubMed1994

Molecular cloning of the rat complement regulatory protein, 5I2 antigen.

We have cloned a cDNA which encoded for rat complement regulatory protein, 5I2 antigen. The deduced amino acid sequence of 497 residues predicted essentially the same domain structure as the mouse complement regulatory protein, Crry/p65, composed of five short consensus repeat (SCR) domains, a transmembrane domain and a cytoplasmic domain. 5I2 antigen, however, had an additional SCR which showed a close similarity to the sixth SCR of mouse complement receptor 1 (CR1) or to the sixth, thirteenth, twentieth and twenty seventh SCR of human CR1. Corresponding domains of 5I2 antigen and mouse Crry/p65 showed 70%-86% amino acid identity, indicating that 5I2 antigen is the rat counterpart of mouse Crry/p65.

Amino Acid Sequence↗
PubMed1994

Comparison of somatic mutation frequency among immunoglobulin genes.

We analyzed the frequency of somatic mutation in immunoglobulin genes from hybridomas that secrete anti-(4-hydroxy-3-nitrophenyl)acetyl (NP) monoclonal antibodies. A high frequency of mutation (3.3-4.4%) was observed in both the rearranged VH186.2 and V lambda 1 genes, indicating that somatic mutation occurs with similar frequency in these genes in spite of the absence of an intron enhancer in lambda 1 chain genes. In contrast to the high frequency in J-C introns, only two nucleotide substitutions occurred at positions -462 and -555 in the 5' noncoding region in one of the lambda 1-chain genes and in none of the other three so far studied. Since a similar low frequency of somatic mutation was observed in the 5' noncoding region of inactive lambda 2-chain genes rendered inactive because of incorrect rearrangement, this region may not be a target or alternatively, may be protected from the mutator system. We observed a low frequency of nucleotide substitution in unrearranged V lambda 1 genes (approximately 1/15 that of rearranged genes). Together with previous results (Azuma T., N. Motoyama, L. Fields, and D. Loh, 1993. Int. Immunol. 5:121), these findings suggest that the 5' noncoding region, which contains the promoter element, provides a signal for the somatic mutator system and that rearrangement, which brings the promoter into close proximity to the enhancer element, should increase mutation efficiency.

Animals↗
PubMed1994

Inducible binding of human lymphocytes to hyaluronate via CD44 does not require cytoskeleton association but does require new protein synthesis.

We have examined molecular mechanisms of the PMA-inducible HA binding ability of human lymphocytes. Newly established OS/6 and OS/37, specific for human CD44, specifically inhibited PMA-induced HA binding of several human cell lines, suggesting that both mAb detect HA binding epitope(s) on CD44. Sequential staining revealed that these mAb cross-blocked each other's binding to Molt-4, T lymphoblast lines, and that neither of them interfered with staining of Molt-4 by other anti-CD44 mAb which induced significant homotypic cell aggregation. Biochemical and PCR analyses did not provide any evidence that PMA stimulation induced dramatic changes in molecular weight or molecular isoforms of CD44. Interestingly, HA binding was not affected and rather slightly increased by cytochalasin B which disrupts F-actin microfilament integrity. This suggests that the ability of CD44 to bind to HA does not correlate with the association of CD44 with the cytoskeleton. On the other hand, protein synthesis inhibitors, cycloheximide and anisomycin clearly inhibited the induction of HA binding of PMA-activated Molt-4 without affecting the expression of CD44 at the same time after stimulation. The same treatment had no effect on PMA-induced FN binding of the cells, which was mediated by VLA integrins. These results suggest that the adhesion functions of CD44 and integrins are differently regulated despite the fact that both are induced by PMA stimulation, and that new protein synthesis is essential for the PMA-induced HA binding by CD44.

Anisomycin↗
PubMed1994

In vitro and in vivo evaluation of thyrotrophin releasing hormone release from copoly(dl-lactic/glycolic acid) microspheres.

In vitro and in vivo release of thyrotrophin releasing hormone (TRH) from copoly(dl-lactic/glycolic acid) (PLGA) microspheres were evaluated. Factors affecting the TRH release from the microspheres were examined to clarify the release mechanisms by changing the medium composition in the in vitro release test. The hydrolysis rate of PLGA, the matrix-forming substance in the microspheres, was faster in acidic medium than in neutral medium. The release rate of TRH from the PLGA microspheres increased with the increase in the degradation rate of PLGA. A decrease in an osmolarity of the medium also caused an increase in the TRH release rate even though no significant change in PLGA degradation was observed. The effect of osmolarity appears to be characteristic of water-soluble drug-containing microspheres composed of hydrophobic polymer. The release rate of TRH from PLGA microspheres was largely affected by the medium composition in the in vitro release test. A proper choice of medium was found to be important for the estimation of in vivo release. The in vivo release rate of TRH from the PLGA microspheres following administration to rats correlated with the in vitro release in pH 7, 1/30 M buffer.

Animals↗
PubMed1994

The nylon oligomer biodegradation system of Flavobacterium and Pseudomonas.

This review article is a compendium of the available information on the degradation of a man-made compound, 6-aminohexanoate-oligomer, in Flavobacterium and Pseudomonas strains, and discusses the molecular basis for adaptation of microorganisms toward these xenobiotic compounds. Three plasmid-encoded enzymes, 6-aminohexanoate-cyclic-dimer hydrolase (EI), 6-aminohexanoate-dimer hydrolase (EII), and endo-type 6-aminohexanoate-oligomer hydrolase (EIII) are responsible for the degradation of the oligomers. Two repeated sequences, designated RS-I and RS-II, are found on plasmid pOAD2, which is involved in 6-aminohexanoate degradation in Flavobacterium. RS-I appears 5 times on the pOAD2, and all copies have the same sequences as insertion sequence IS6100. RS-II appears twice on the plasmid. RS-IIA contains the gene encoding EII, while RS-IIB contains the gene for the analogous EII' protein. Both EII and EII' are polypeptides of 392 amino acids, which differ by 46 amino acid residues. The specific activity of the EII enzyme is 200-fold higher than that of EII'. Construction of various hybrid genes demonstrated that only the combination of two amino acid residues in the EII' enzyme can enhance the activity of the EII' to the same level as that of EII enzyme.

Amino Acid Sequence↗
PubMed1994

Anti-(glioma surface antigen) monoclonal antibody G-22 recognizes overexpressed CD44 in glioma cells.

We raised an anti-glioma monoclonal antibody, named G-22, that specifically recognizes a human glioma-associated surface antigen. Proven to be useful for target imaging of malignant gliomas after radioisotope labeling and cerebrospinal fluid diagnosis by enzyme-linked immunospecific assay, G-22 was found to immunoprecipitate an 85-kDa glycoprotein of the human glioma U-251MG cell. We purified this antigen by G-22-coupled cyanogenbromide-activated Sepharose affinity chromatography, and sequence analysis demonstrated that the 54 amino acid residues were identical to positions 55-108 of human CD44. The results show that the smallest spliced form (85 kDa) of CD44 is strongly expressed in glioma cells.

Amino Acid Sequence↗
PubMed1994

The addition of glutathione (YM737) to a crystalloid cardioplegic solution enhances myocardial protection.

The effectiveness of a glutathione preparation, YM737, as a free radical scavenger when added to hypothermic (4 degrees C) crystalloid cardioplegic solution was evaluated in this study. Rabbit hearts were preserved for 3 h in cardioplegic arrest by infusing 20 ml crystalloid cardioplegic solution initially, with additional 10-ml boluses administered every 30 min, while maintaining a myocardial temperature of 10 degrees C. They were then reperfused with Krebs-Henseleit bicarbonate buffer at 37 degrees C in a perfusion circuit for 60 min. The hearts were divided into two groups of six: One in which crystalloid cardioplegic solution was perfused (group 1); and one in which crystalloid cardioplegic solution containing YM737 1 mg/ml was perfused (group 2). The postischemic developed pressure (mmHg) in group 2 was significantly greater than that in group 1 after 60 min of reperfusion, being 44.8 +/- 8.4 versus 87.8 +/- 5.2 in groups 1 and 2, respectively (P < 0.01). Moreover, group 2 exhibited significantly lower postischemic left ventricular compliance after 60 min than group 1 (P < 0.01) and a significantly higher postischemic peak LV dp/dt (mmHg/sec) after 60 min of reperfusion, being 925 +/- 213 versus 1,550 +/- 111 in groups 1 and 2, respectively (P < 0.05). Based on the comparisons of postischemic hemodynamics it was concluded that the addition of glutathione to crystalloid cardioplegic solution does in fact enhance myocardial protection.

Animals↗
PubMed1994

Sleep-related changes in human muscle and skin sympathetic nerve activities.

To characterize the features of sympathetic nerve activity during non-REM sleep, we measured the muscle and skin sympathetic nerve activities (MSNA and SSNA, respectively) using a double recording microneurographic technique. Eight healthy volunteers were monitored by polysomnography (including EEG, EOG, EMG, and ECG) and received acoustic stimuli (880 Hz, 125 ms) during sleep stage 2. The specific discharge properties of MSNA during wakefulness included pulse-synchronicity, short burst duration and a non-responsiveness to arousal stimuli. These were considered to be generated by an inhibitory input from the baroreceptors to the cardiovascular center. In contrast, SSNA lacked pulse-synchronicity, had longer bursts, and was responsive to a variety of stimuli. Burst rates of MSNA and SSNA were reduced during sleep stages 1 and 2 (light sleep) vs. during a wakefulness. Both MSNA and SSNA appeared to be related to spontaneously occurring K-complexes. The baroreflex latency (from the ECG R-wave to the integrated MSNA burst peak) was constant at approximately 1.20 s during sleep, suggesting that pulse-synchronicity was maintained. The MSNA burst evolution time (interval between initiation of the burst and its peak) became longer with a transition to deeper non-REM sleep stages, whereas the SSNA burst evolution times remained constant. K-complexes induced by acoustic stimuli were frequently accompanied by MSNA and/or SSNA. MSNA responded to acoustic stimuli during light sleep, but some bursts lacked a close relation in time to cardiac rhythm.(ABSTRACT TRUNCATED AT 250 WORDS)

Acoustic Stimulation↗
PubMed1994

The significance of gonadotropin-releasing hormone test for predicting fertility after varicocelectomy.

To predict the surgical outcome in 30 infertile men with varicocele, endocrinologic evaluation by the GnRH test was performed before and 6 months after the high ligation of the left internal spermatic vein. Semen analysis was performed and the levels of basal T and PRL were examined preoperatively and 6 months postoperatively. In the pregnancy group, the preoperative excessive response of LH to the GnRH test decreased significantly after surgery. Significant reduction in the LH response is considered to be a valuable parameter for predicting fertility.

Adult↗
PubMed1994

Interleukin-1 alpha and interleukin-1 beta periapical exudates of infected root canals: correlations with the clinical findings of the involved teeth.

This study quantified the concentrations of interleukin-1 alpha (IL-1 alpha) and interleukin-1 beta (IL-1 beta) in the periapical exudates obtained from 69 single-rooted teeth using enzyme-linked immunosorbent assays, and examined their correlation with clinical findings of the involved teeth. Changes in the levels of these factors during root canal treatment were also investigated. The average levels of IL-1 beta (6.57 ng/ml) in periapical exudates were twice that of IL-1 alpha (3.25 ng/ml). The exudates containing pus showed significantly higher IL-1 alpha levels than those from the canals without pus (p < 0.01). The exudates from the canals with small radiolucent areas contained significantly higher IL-1 alpha levels than those from the canals with large radiolucent areas (p < 0.05). The tendency for there to be an increase in the levels of IL-1 alpha and a decrease in the levels of IL-1 beta was observed following root canal treatment. These observations suggest that IL-1 alpha and IL-1 beta are involved in the immunopathogenesis of periapical lesions and that IL-1 alpha and IL-1 beta may play different roles in the healing process of periapical lesions during root canal treatment.

Dental Pulp Diseases↗
PubMed1994

Partial characterization of a low molecular weight phagocytosis inhibitory factor obtained from human erythrocyte membranes.

Phagocytosis Inhibitory Factor (PIF), a small (< 3000 D) molecule, was partially purified from human red blood cell membranes. This factor inhibits latex phagocytosis by monocytic cells. PIF is not toxic under the experimental conditions employed and the phagocytosis inhibitory activity is reversible since removal of this factor restores the phagocytic capability of cells. The phagocytic activity of murine macrophages was not affected by PIF.

Animals↗
PubMed1994

Interleukin-4 expression in mesangial proliferative glomerulonephritis.

Several cytokines are known to play roles in the pathogenesis of human glomerulonephritis. Recently, some studies proposed a possible relationship between interleukin-4 (IL-4) and glomerulonephritis. To investigate the involvement of IL-4 in human glomerulonephritis, we evaluated renal biopsy specimens using immunohistochemical procedures. Our study revealed that the glomeruli in immunoglobulin A nephropathy and lupus nephritis (World Health Organization grades II and IV) contained IL-4-positive cells, which were CD-3- and CD-4-positive T lymphocytes. CD-8-, CD-14-, CD-19-, or CD-56-positive cells did not react with anti-IL-4. CD-23-positive cells were not observed in the sections used in this study. Interleukin-4-positive cells were not found in the normal control kidney tissues. The degree of the glomerular IL-4-positive cell index correlated well with the glomerular hypercellularity index, but not with any other clinical or histopathologic parameters. Therefore, the present study offers more reliable evidence concerning the association between IL-4 and human glomerulonephritis.

Adult↗
PubMed1994

Sustained suppression of the pituitary-gonadal axis by leuprorelin three-month depot microspheres in rats and dogs.

The pharmacological effects of leuprorelin three-month depot microspheres were investigated in rats and dogs. After s.c. and i.m. injection, the microspheres provided similar linear drug release and sustained serum drug levels for 3 months. Persistent suppression of serum LH, FSH (in rats) and testosterone (in rats and dogs) for over 16 weeks was achieved when the microspheres were given at a dose of 100 (rat) and 25.6 (dog) micrograms/kg/day. These hormone release responses upon periodic challenge tests revealed that a single injection of the microspheres caused dramatic suppression of the function of the pituitary-gonadal system for 15 weeks in rats. The growth of the genital organs was also suppressed dose-dependently by injection of the microspheres over 3 months; the strongest suppression was achieved at a dose of 100 micrograms/kg/day. This three-month depot formulation is expected to be more convenient than the one-month depot with improved patient compliance and therapeutic effects.

Animals↗
PubMed1994

Preparation of three-month depot injectable microspheres of leuprorelin acetate using biodegradable polymers.

To obtain a three-month release injection of leuprorelin acetate, microspheres were prepared with copoly(DL-lactic/glycolic acid) or poly(DL-lactic acid) (PLA) using an in-water drying method, and drug release was evaluated. The content of water-soluble oligomers in the polymers was found to strongly affect the initial burst, and reducing the content to less than 0.1% was necessary to keep the first-day release below 10%. Drug loading of more than 15% also increased the initial drug release; the acceptable maximum loading was 12%. Elevation of the glass transition temperature of the microspheres was observed with an increase in drug loading. This suggests formation of a rigid structure, possibly with arrangement of the polymer around the drug cores like in a micelle. This structure provides a hydrophobic barrier against diffusion of the hydrophilic peptide, resulting in high trapping efficiency and long-term sustained release dependent on polymer erosion. The microspheres prepared with PLA having a m.w. of 12,000 to 18,000 provided linear sustained release and persistent serum levels of the drug in rats for over 3 months.

Acids↗
PubMed1994

Insulin fragments as a carrier for peptide delivery across the blood-brain barrier.

The possibility of using insulin (INS), which is transported into the brain by receptor-mediated transcytosis, as a peptide carrier for delivery across the blood-brain barrier (BBB) was investigated. After mice received an i.v. injection of horseradish peroxidase (HRP, M.W., 40,000) conjugated with INS, the HRP activity in the brain was higher than that after HRP injection. Since INS-HRP lowered the blood glucose level, we prepared insulin fragments by chemical and enzymatic procedures in an effort to find a carrier with no hypoglycemic activity. Seven fragments were synthesized taking the binding regions into consideration, but none showed any receptor binding affinity in cultures of bovine brain microvessel endothelial cells (BMEC). However, the fragment (F007) obtained by trypsin digestion showed high affinity and scarcely any hypoglycemic activity in mice even at a dose ten times the effective dose of insulin. These results suggest that this fragment may be useful as a carrier to transport therapeutic peptides across the BBB.

Amino Acid Sequence↗
PubMed1994

Localization of the complement regulatory proteins in the normal human kidney.

The kidney is an organ where complement-mediated tissue injuries take place by various stimuli. To assess how the kidney is protected from the autologous complement attack, comparative localization of decay accelerating factor (DAF), membrane cofactor protein (MCP) and 20 kDa homologous restriction factor (HRF20) was studied in the normal human kidney. Specific monoclonal antibodies to DAF, MCP and HRF20 were used for the study. Studies by immunofluorescence and immunoelectron microscopy showed that the distribution of each protein in the kidney was complementary to each other in most parts. MCP and HRF20 were clearly seen in the glomerular capillaries, while DAF was only faintly observed. Juxtaglomerular apparatus was abundant in DAF and MCP but not in HRF20. HRF20 was most strongly expressed in the peritubular capillaries where MCP was not detectable. Basolateral membranes of the proximal tubules and collecting ducts expressed MCP strongly, while there was no expression of DAF in the proximal tubules. Interestingly, both DAF and MCP, which inhibit complement activation at C3/C4 level, were not expressed in the apical portion of the tubular cells including proximal tubule brush border. In contrast, HRF20 was expressed on the apical part of the tubules. Medullary interstitium strongly expressed MCP but not DAF. Based on these observations, we conclude that each segment of the kidney is protected from the complement attack by the different combination of complement regulatory proteins. We speculate that the tubular cells might be fragile when complements are activated inside the tubular lumen, because there is no expression of complement regulatory proteins which inhibit C3 convertase.

Antibodies, Monoclonal↗